Diplomat Pharmacy, Inc. (NYSE:DPLO) Receives Consensus Rating of “Hold” from Analysts
Shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) have earned an average rating of “Hold” from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.89.
A number of analysts have recently commented on the company. Bank of America Corporation lifted their target price on Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a research report on Thursday, May 25th. BidaskClub cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Cowen and Company lifted their target price on Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 9th. Needham & Company LLC assumed coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They set a “buy” rating and a $19.75 target price on the stock. Finally, Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.
Several institutional investors have recently added to or reduced their stakes in DPLO. Victory Capital Management Inc. raised its position in Diplomat Pharmacy by 5.8% in the second quarter. Victory Capital Management Inc. now owns 1,017,210 shares of the company’s stock worth $15,055,000 after buying an additional 56,070 shares in the last quarter. Marshall Wace North America L.P. bought a new position in Diplomat Pharmacy during the second quarter worth about $935,000. Frontier Capital Management Co. LLC raised its position in Diplomat Pharmacy by 4.1% in the second quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock worth $84,023,000 after buying an additional 221,769 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Diplomat Pharmacy by 57.6% in the second quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock worth $207,000 after buying an additional 5,116 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Diplomat Pharmacy by 8.9% in the second quarter. Legal & General Group Plc now owns 85,471 shares of the company’s stock worth $1,265,000 after buying an additional 6,964 shares in the last quarter. 72.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Diplomat Pharmacy (NYSE DPLO) opened at 15.26 on Tuesday. The firm’s 50-day moving average price is $16.05 and its 200 day moving average price is $15.66. The stock has a market cap of $1.02 billion, a P/E ratio of 60.80 and a beta of 0.66. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, August 7th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 7.91% and a net margin of 0.38%. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.14 billion. During the same quarter in the previous year, the firm earned $0.23 earnings per share. The business’s revenue was up 3.5% compared to the same quarter last year. On average, equities analysts expect that Diplomat Pharmacy will post $0.66 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/diplomat-pharmacy-inc-nysedplo-receives-consensus-rating-of-hold-from-analysts.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.